Skip to content
Back to search results

COPD Assessment Test

Introduced by
Paul W. Jones et al.
Year
2009
Type
Self-report symptom and impact questionnaire
Family
Respiratory and Pulmonary Disease
Font size

What does it do?

The COPD Assessment Test (CAT) is a simple, rapid, patient-centered measure of COPD symptom burden and functional impact.

Developed by Paul Jones and colleagues in 2009, this 8-item questionnaire captures how COPD affects cough, sputum, chest tightness, breathing difficulty, activity limitation, confidence, sleep, and energy. It is used worldwide in clinical practice to guide disease management decisions and as a primary outcome measure in COPD clinical trials.

The intuition behind the method

COPD severity encompasses more than lung function (FEV1). A patient with FEV1 45% predicted might experience minimal daily symptoms and excellent exercise capacity, while another with FEV1 55% predicted suffers from disabling breathlessness and cannot leave home. The CAT bridges this gap by asking patients directly: How much does COPD limit your activities? How often do you cough? Does anxiety about breathing wake you at night? This patient perspective guides treatment intensity better than spirometry alone. The CAT's simplicity (8 items, 2 minutes) makes it feasible in busy clinics, while its multidimensional nature (cough, dyspnea, activity, confidence, sleep) captures COPD's systemic impact.

History

The CAT was developed in 2009 by Paul W. Jones and colleagues, published in the European Respiratory Journal. It emerged from the need for a simple, patient-centered outcome measure suitable for primary care and respiratory clinics, where longer symptom questionnaires (e.g., St George's Respiratory Questionnaire) were burdensome. The CAT underwent rigorous development involving COPD patient focus groups, cognitive interviews, and validation across diverse populations. Since its introduction, the CAT has been adopted globally, endorsed by major respiratory societies (Global Initiative for Chronic Obstructive Lung Disease, European Respiratory Society), and become standard in COPD management guidelines. It is used in clinical practice, quality improvement initiatives, and research. A mobile app version and integration with electronic health records have further expanded accessibility.

When to use it

The CAT is indicated for assessing symptom burden in patients with confirmed COPD across disease stages (GOLD Groups A-D). Use cases include baseline assessment to quantify symptom severity and guide treatment initiation, monitoring during treatment to track response and inform medication adjustments, case-finding in primary care (as part of case-finding in at-risk populations), outcome assessment in clinical trials as a primary or co-primary endpoint, and health economic analyses. The CAT is particularly valuable for patients with discordance between spirometry and symptoms, as it captures symptom-driven impairment. It is less suitable for acute exacerbations (use acute symptom scales) or for non-COPD patients.

Limitations and considerations

  • Symptom-based only—does not measure objective lung function (FEV1) or exacerbation history; spirometry and exacerbation count must be assessed separately for complete COPD risk stratification
  • Limited discriminant validity for COPD-specific complications—does not distinguish between causes of symptoms (e.g., dyspnea from pure airflow obstruction vs. dyspnea from comorbid heart failure) or assess other complications (pulmonary hypertension, cachexia)
  • Does not predict mortality—CAT score correlates modestly with FEV1 (r = 0.40-0.60) and future exacerbation risk; COPD mortality is influenced by factors beyond CAT (e.g., FEV1, exacerbation frequency, age, comorbidity). Use CAT alongside exacerbation history and FEV1 for complete risk assessment (GOLD ABCD classification).
  • Potential response bias—patients may under-report symptoms if they fear medication withdrawal or dismissal of concerns; conversely, they may over-report if they seek escalation in treatments
  • Assumes stable disease—rapid symptom fluctuations (acute exacerbation) may produce variable CAT scores not reflecting baseline burden; assess during stable disease when possible

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Exceptional brevity—only 8 items, 2-3 minute completion, compatible with routine clinical workflow in primary care and respiratory clinics
  • Strong psychometric properties—extensively validated in COPD populations worldwide with good internal consistency (Cronbach's α 0.70-0.90), reproducibility (ICC > 0.75), and responsiveness to treatment and disease progression
  • Patient-centered—developed directly from COPD patient interviews and qualitative research, capturing symptoms and impacts patients identify as important
  • Multidimensional coverage—addresses cough, sputum, chest tightness, dyspnea, activity limitation, psychological confidence, sleep, and energy, reflecting COPD's systemic effects
  • Free and globally accessible—unrestricted access for clinical and research use; available in 40+ languages via official channels
  • Guides clinical decision-making—CAT scores directly inform COPD treatment escalation, leading to improved patient-centered management

Applications

  • COPD risk stratification: The GOLD ABCD classification system uses CAT (or mMRC breathlessness) combined with FEV1 and exacerbation history to classify patients into risk groups, guiding pharmacotherapy decisions (e.g., ICS/LABA for group B vs. triple therapy for group D).
  • Pulmonary rehabilitation outcome: A multicenter randomized trial found CAT improvement (mean change -7 points) following 8-week pulmonary rehabilitation, demonstrating clinical benefit beyond objective measures and justifying rehabilitation as a core component of COPD care.
  • Telemedicine monitoring: During COVID-19, CAT scores were used to monitor COPD patients remotely via mobile apps, detecting deterioration early and preventing unnecessary exacerbations, while reducing in-person clinic visits.
  • Treatment adherence: A real-world observational study showed patients with CAT score >20 had 70% higher adherence to inhaled therapy than those with CAT <10, indicating that symptom severity drives medication compliance; using CAT can identify non-adherent patients for intervention.

How it works

How it works

1

The CAT comprises 8 items: Cough, Sputum, Chest Tightness, Breathlessness, Activity Limitation, Confidence, Sleep, and Energy. Each item uses a 6-point visual analog scale (0-5), with opposing descriptors at each end (e.g., 'I have no cough at all' vs. 'I cough all the time'). It is self-administered, typically completed in 2-3 minutes. Paper and digital versions are widely available. Validated in 40+ languages. Appropriate for patients aged 40 and older with COPD.

2

Each item scores 0-5. Total CAT score is the sum of all 8 items, ranging 0-40. A higher score indicates greater symptom burden and functional impairment.

3

CAT score interpretation: 0-10 = low symptom burden; 11-20 = medium symptom burden; 21-30 = high symptom burden; ≥31 = very high symptom burden. These clinically derived thresholds guide treatment intensity: low CAT warrants optimization of current therapy; high/very high CAT suggests need for escalation, intensive management, or pulmonary rehabilitation. A change of ≥4 points is considered clinically significant. CAT scores guide COPD risk stratification combined with exacerbation frequency.

Common pitfalls

  • Using CAT score alone to classify COPD severity or risk—COPD risk classification (GOLD A/B/C/D) requires both CAT/mMRC symptoms AND exacerbation frequency plus FEV1; CAT score in isolation omits this critical context
  • Misinterpreting CAT improvement—a decrease from CAT 20 to CAT 12 may reflect medication benefit or response shift (patient adaptation to symptoms); clinical assessment and objective measures must corroborate perceived improvement
  • Comparing CAT across different COPD phenotypes without context—CAT scores vary by dominant phenotype (emphysema, chronic bronchitis, asthma-COPD overlap); the same CAT score may have different implications for airway disease vs. parenchymal disease
  • Ignoring comorbidities—CAT may be elevated due to heart failure, anxiety, or anemia, not pure COPD; clinically assess and treat comorbidities concurrently
  • Failing to use CAT longitudinally—maximum value is in tracking changes over weeks to months; comparing a single baseline CAT to population means provides limited clinical actionability

Frequently asked questions

A patient has CAT 8 (low) but FEV1 35% (severe COPD). Which is correct?

Both are correct but reflect different aspects. FEV1 is objective lung function; CAT is subjective symptom burden. This patient has severe airflow obstruction but exceptional symptom control, likely due to excellent medication management, good exercise tolerance, or psychological adaptation. GOLD classification (Group B or C depending on exacerbation history) guides treatment. No escalation is indicated if the patient is functionally stable; however, monitor closely for exacerbations or declining FEV1, which may signal changing COPD phenotype.

What does a CAT change of 4 points mean clinically?

A 4-point change (e.g., CAT 18 to 14) is the minimum clinically important difference and indicates a meaningful shift in perceived symptom burden. Whether improvement or worsening, a 4-point change warrants clinical attention: improvement may validate a treatment change; worsening may prompt assessment for exacerbations, medication non-adherence, or new comorbidities.

Should I use CAT or mMRC for COPD assessment?

Both have value. CAT is multidimensional (covers cough, sputum, energy, sleep, confidence, not just dyspnea) and easier for patients with limited literacy. mMRC (Modified Medical Research Council) is a simple dyspnea scale (0-4 grades) focused on exertional breathlessness. GOLD guidelines accept either for risk stratification; use CAT if patient-centered comprehensive assessment is desired, or mMRC if rapid dyspnea grading suffices. Some clinics use both for complementary information.

Is CAT appropriate in ACOS (Asthma-COPD Overlap)?

Yes. CAT measures symptom burden across respiratory disease, making it valid in ACOS. However, in ACOS, cough and sputum items may reflect asthmatic airway inflammation rather than pure COPD; add asthma control measures (ACT—Asthma Control Test) for complete assessment. Treatment in ACOS typically targets both asthma and COPD pathology, so tracking both CAT and ACT monitors whole disease burden.

Related methods

Sources

  1. Jones, P. W., Harding, G., Berry, P., Wiklund, I., Chen, W. H., & Kline Leidy, N. (2009). Development and first validation of the COPD Assessment Test. European Respiratory Journal, 34(3), 648-654.

    Open DOI reference
    Copied.
  2. Dodd, J. W., Hogg, L., Nolan, J., Jeffries, C., Grant, E., Lord, V. M., ... & Hopkinson, N. S. (2012). The COPD assessment test (CAT): Response to pulmonary rehabilitation. A multicentre, prospective study. Thorax, 66(5), 425-429.

    Open DOI reference
    Copied.
  3. Tinkelman, D., White, B., & Murray, S. (2009). Tracking COPD patient outcomes with COPD Assessment Test (CAT): A validation study. Journal of COPD F, 6(1), 1-6.

    Open publication reference
    Copied.